Brief: Immuneonco Biopharmaceuticals Shanghai Says Obtained Investigational New Drug Approval
16/10/2023 11:32
Oct 16 (Reuters) - ImmuneOnco Biopharmaceuticals
Shanghai Inc 1541.HK :
* OBTAINED INVESTIGATIONAL NEW DRUG APPROVAL FOR IMM47 FOR
TREATMENT OF SOLID TUMORS
* APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF
PEOPLE'S REPUBLIC OF CHINA
Further company coverage: 1541.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S